221 related articles for article (PubMed ID: 25345808)
1. Toll-like receptor agonists shape the immune responses to a mannose receptor-targeted cancer vaccine.
He LZ; Weidlick J; Sisson C; Marsh HC; Keler T
Cell Mol Immunol; 2015 Nov; 12(6):719-28. PubMed ID: 25345808
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells.
Ramakrishna V; Vasilakos JP; Tario JD; Berger MA; Wallace PK; Keler T
J Transl Med; 2007 Jan; 5():5. PubMed ID: 17254349
[TBL] [Abstract][Full Text] [Related]
3. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin beta.
He LZ; Ramakrishna V; Connolly JE; Wang XT; Smith PA; Jones CL; Valkova-Valchanova M; Arunakumari A; Treml JF; Goldstein J; Wallace PK; Keler T; Endres MJ
Clin Cancer Res; 2004 Mar; 10(6):1920-7. PubMed ID: 15041707
[TBL] [Abstract][Full Text] [Related]
4. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients.
Morse MA; Chapman R; Powderly J; Blackwell K; Keler T; Green J; Riggs R; He LZ; Ramakrishna V; Vitale L; Zhao B; Butler SA; Hobeika A; Osada T; Davis T; Clay T; Lyerly HK
Clin Cancer Res; 2011 Jul; 17(14):4844-53. PubMed ID: 21632857
[TBL] [Abstract][Full Text] [Related]
5. Antigenic targeting of the human mannose receptor induces tumor immunity.
He LZ; Crocker A; Lee J; Mendoza-Ramirez J; Wang XT; Vitale LA; O'Neill T; Petromilli C; Zhang HF; Lopez J; Rohrer D; Keler T; Clynes R
J Immunol; 2007 May; 178(10):6259-67. PubMed ID: 17475854
[TBL] [Abstract][Full Text] [Related]
6. CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.
Morse MA; Bradley DA; Keler T; Laliberte RJ; Green JA; Davis TA; Inman BA
Expert Rev Vaccines; 2011 Jun; 10(6):733-42. PubMed ID: 21692696
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.
Trumpfheller C; Longhi MP; Caskey M; Idoyaga J; Bozzacco L; Keler T; Schlesinger SJ; Steinman RM
J Intern Med; 2012 Feb; 271(2):183-92. PubMed ID: 22126373
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
Grossmann C; Tenbusch M; Nchinda G; Temchura V; Nabi G; Stone GW; Kornbluth RS; Uberla K
BMC Immunol; 2009 Aug; 10():43. PubMed ID: 19650904
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant.
Kass E; Panicali DL; Mazzara G; Schlom J; Greiner JW
Cancer Res; 2001 Jan; 61(1):206-14. PubMed ID: 11196163
[TBL] [Abstract][Full Text] [Related]
10. Activation of toll-like receptor signaling pathway for protection against influenza virus infection.
Wong JP; Christopher ME; Viswanathan S; Karpoff N; Dai X; Das D; Sun LQ; Wang M; Salazar AM
Vaccine; 2009 May; 27(25-26):3481-3. PubMed ID: 19200852
[TBL] [Abstract][Full Text] [Related]
11. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines.
Disis ML; Bernhard H; Shiota FM; Hand SL; Gralow JR; Huseby ES; Gillis S; Cheever MA
Blood; 1996 Jul; 88(1):202-10. PubMed ID: 8704175
[TBL] [Abstract][Full Text] [Related]
13. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.
Ramakrishna V; Treml JF; Vitale L; Connolly JE; O'Neill T; Smith PA; Jones CL; He LZ; Goldstein J; Wallace PK; Keler T; Endres MJ
J Immunol; 2004 Mar; 172(5):2845-52. PubMed ID: 14978085
[TBL] [Abstract][Full Text] [Related]
14. A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract.
Ruane D; Do Y; Brane L; Garg A; Bozzacco L; Kraus T; Caskey M; Salazar A; Trumpheller C; Mehandru S
Mucosal Immunol; 2016 Sep; 9(5):1340-52. PubMed ID: 26732678
[TBL] [Abstract][Full Text] [Related]
15. TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial.
Everson RG; Hugo W; Sun L; Antonios J; Lee A; Ding L; Bu M; Khattab S; Chavez C; Billingslea-Yoon E; Salazar A; Ellingson BM; Cloughesy TF; Liau LM; Prins RM
Nat Commun; 2024 May; 15(1):3882. PubMed ID: 38719809
[TBL] [Abstract][Full Text] [Related]
16. A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.
Melssen MM; Petroni GR; Chianese-Bullock KA; Wages NA; Grosh WW; Varhegyi N; Smolkin ME; Smith KT; Galeassi NV; Deacon DH; Gaughan EM; Slingluff CL
J Immunother Cancer; 2019 Jun; 7(1):163. PubMed ID: 31248461
[TBL] [Abstract][Full Text] [Related]
17. The toll-like receptor ligands Hiltonol
Patchett AL; Tovar C; Corcoran LM; Lyons AB; Woods GM
Dev Comp Immunol; 2017 Nov; 76():352-360. PubMed ID: 28689773
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Thomann JS; Heurtault B; Weidner S; Brayé M; Beyrath J; Fournel S; Schuber F; Frisch B
Biomaterials; 2011 Jul; 32(20):4574-83. PubMed ID: 21474175
[TBL] [Abstract][Full Text] [Related]
19. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
Tsuji T; Matsuzaki J; Kelly MP; Ramakrishna V; Vitale L; He LZ; Keler T; Odunsi K; Old LJ; Ritter G; Gnjatic S
J Immunol; 2011 Jan; 186(2):1218-27. PubMed ID: 21149605
[TBL] [Abstract][Full Text] [Related]
20. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Xu YY; Kalos M; Cai L; Fang HB; Weiss BM; Badros A; Yanovich S; Akpek G; Tsao P; Cross A; Mann D; Philip S; Kerr N; Brennan A; Zheng Z; Ruehle K; Milliron T; Strome SE; Salazar AM; Levine BL; June CH
Clin Cancer Res; 2014 Mar; 20(5):1355-65. PubMed ID: 24520093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
